The Relationship between a New Biomarker of Vagal Neuroimmunomodulation and Survival in Two Fatal Cancers

por Gidron, Y., De Couck, M., Schallier, D., De Greve, J., Van Laethem, J. L., Maréchal, R.
Publicado 2018

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study

por Demols, A, Peeters, M, Polus, M, Marechal, R, Gay, F, Monsaert, E, Hendlisz, A, Van Laethem, J L
Publicado 2006

Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer

por Roeyen, G., Berrevoet, F., Borbath, I., Geboes, K., Peeters, M., Topal, B., Van Cutsem, E., Van Laethem, J.-L.
Publicado 2022

DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer

por Drouillard, A, Puleo, F, Bachet, J B, Ouazzani, S, Calomme, A, Demetter, P, Verset, G, Van Laethem, J L, Maréchal, R
Publicado 2016

High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma

por Maréchal, R, Demetter, P, Nagy, N, Berton, A, Decaestecker, C, Polus, M, Closset, J, Devière, J, Salmon, I, Van Laethem, J-L
Publicado 2009

High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma

por Maréchal, R, Demetter, P, Nagy, N, Berton, A, Decaestecker, C, Polus, M, Closset, J, Devière, J, Salmon, I, Van Laethem, J-L
Publicado 2010

Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study

por Verset, G, Verslype, C, Reynaert, H, Borbath, I, Langlet, P, Vandebroek, A, Peeters, M, Houbiers, G, Francque, S, Arvanitakis, M, Van Laethem, J-L
Publicado 2007

Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study

por Van Cutsem, E, Dirix, L, Van Laethem, J-L, Van Belle, S, Borner, M, Gonzalez Baron, M, Roth, A, Morant, R, Joosens, E, Gruia, G, Sibaud, D, Bleiberg, H
Publicado 2005

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic a...

por Ramanathan, R. K., Goldstein, D., Korn, R. L., Arena, F., Moore, M., Siena, S., Teixeira, L., Tabernero, J., Van Laethem, J.-L., Liu, H., McGovern, D., Lu, B., Von Hoff, D. D.
Publicado 2016

Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study

por Van Cutsem, E, Li, C-P, Nowara, E, Aprile, G, Moore, M, Federowicz, I, Van Laethem, J-L, Hsu, C, Tham, C K, Stemmer, S M, Lipp, R, Zeaiter, A, Fittipaldo, A, Csutor, Z, Klughammer, B, Meng, X, Ciuleanu, T
Publicado 2014

Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic cancer

por Nicolle, R., Gayet, O., Bigonnet, M., Roques, J., Chanez, B., Puleo, F., Augustin, J., Emile, J.F., Svrcek, M., Arsenijevic, T., Hammel, P., Rebours, V., Giovannini, M., Grandval, P., Dahan, L., Moutardier, V., Mitry, E., Van Laethem, J.L., Bachet, J.B., Cros, J., Iovanna, J., Dusetti, N.J.
Publicado 2021